ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Session » Rheumatoid Arthritis - Clinical Aspects: Novel Biomarkers and Other Measurements of Disease Activity

Meeting: 2014 ACR/ARHP Annual Meeting

Abstract Number: 348
Smoking Status Is Associated with Inflammatory Cytokine Profile and Disease Activity: Decreased Inflammation and Disease Improvement with Smoking Cessation?
Abstract Number: 349
Galectin-3 in the Systemic Circulation Is Increased in Newly Diagnosed Rheumatoid Arthritis and Is Associated with Anti-CCP and Bone Marrow Edema
Abstract Number: 350
Rho-Associated Protein Kinase (ROCK) Activity Is Elevated in Rheumatoid Arthritis (RA) Patients and May be Responsive to RA Therapies
Abstract Number: 351
Doctor, Will My Fatigue be Better If I’m in Remission? an Exploratory Analysis of 1284 Rheumatoid Arthritis (RA) Patients Indicates Fatigue Is the Only Aspect of Patient-Perceived Impact to Remain Significant in ACR/EULAR Boolean Remission
Abstract Number: 352
Remaining Pain in Spite of Suppressed Inflammation in Early Rheumatoid Arthritis – Long-Term Strongly Increased Risk for Widespread Pain and Fatigue
Abstract Number: 353
Sensitivity of Unique Multidimensional Health Assessment Questionnaire Items Compared to Items on Both the HAQ and MDHAQ in Patients with RA and SLE
Abstract Number: 354
Increased Vascular Wall Inflammation in Patients with Active Rheumatoid Arthritis As Measured By an 18F-FDG-PET/CT Scan
Abstract Number: 355
Increased Left Ventricular Mass Index and Decreased Ejection Fraction Are Associated with Disease Activity in Rheumatoid Arthritis Patients without Cardiac Symptoms; Comparison Between Non-Biologic and Biologic Dmards Treatment Groups, Using a Cardiac Magnetic Resonance Imaging
Abstract Number: 356
The Rheumatoid Arthritis Impact of Disease Score Is Associated with Disease Activity By Clinical, Laboratory and Ultrasonographic Measures: Validation in an inception Cohort of DMARD naïve Patients with Rheumatoid Arthritis
Abstract Number: 357
Development and Validation of a Diagnostic Bead-Based Multiplex Autoantibody Assay:Screening for Autoantibodies to Detect “Seronegative” Rheumatoid Arthritis
Abstract Number: 358
Parity and Severity of ACPA-Positive/Negative Rheumatoid Arthritis. Results from the Swedish EIRA Study
Abstract Number: 359
14-3-3η Cit:Arg Antibody Ratios:  Are We Overlooking the Prognostic Utility of Citrullinated Antibodies By Only Looking at Titers?
Abstract Number: 360
88% of Recent Onset Polyarthritis Patients Are Positive for 14-3-3η Markers and 14-3-3η Auto-Antibodies Inform a Favourable Prognosis
Abstract Number: 361
Citrullinated 14-3-3η Antibodies Are Specific for Early and Established RA and Are Complementary to ACPA
Abstract Number: 362
14-3-3η Early RA Biomarkers: Does Seronegative RA Exist?
Abstract Number: 363
Increased Prevalence of Plasma Anti-Nuclear, Anti-SSA, and Connective Tissue Disease Associated Antibodies in African American Patients with Rheumatoid Arthritis
Abstract Number: 364
In Early Rheumatoid Arthritis, the Multi-Biomarker Disease Activity Score at Different Time-Points Is Predictive of Subsequent Radiographic Progression
Abstract Number: 365
Differential Relative Contribution of Individual Components on DAS28 over Time: An Analysis from the Prospective, Observational, Biological Treatment Registry Across Canada
Abstract Number: 366
Soluble 4-1BB Is a Marker of Joint Involvement and Disease Activity in Rheumatoid Arthritis
Abstract Number: 367
In Early Rheumatoid Arthritis Patients with Non-Response to Methotrexate Monotherapy the Change in Multi-Biomarker Disease Activity Score Is Differentially Associated with Subsequent Response to Non-Biological Versus Biological Therapy
Abstract Number: 368
Serum C1M Level Predicts Disease Progression and Early Treatment Efficacy in Rheumatoid Arthritis
Abstract Number: 369
Validation of Snapshot, a Rheumatoid Arthritis Assessment Tool, Against CDAI, DAS28 (ESR), and DAS28 (CRP)  in Canadian Patients with Rheumatoid Arthritis
Abstract Number: 370
Double Positivity of RA Serologies More Prevalent Yet Associated with Clinical Response in Ethnic Minority Patients with Rheumatoid Arthritis
Abstract Number: 371
The Impact of Missing Anti-Citrullinated Protein Antibody (ACPA) on Outcomes in Early Rheumatoid Arthritis: From the Canadian Early Arthritis Cohort
Abstract Number: 372
Diagnostic Accuracy and Associated Costs of Rheumatoid Factor Testing in Primary Care: A Population-Based Cohort Study in Spain
Abstract Number: 373
Biomarkers of Cardiac Dysfunction and Inflammation in Plasma Predict Occult Coronary Plaque Burden and Composition in Rheumatoid Arthritis
Abstract Number: 374
IL-33 and Soluble ST2 Levels As Novel Predictors for Remission and Progression of Carotid Plaque in Early Rheumatoid Arthritis: A Prospective Study
Abstract Number: 375
Evaluation of RAPID3 with Minimal Joint Count and ACR/EULAR Provisional Remission Definitions As Predictors of Future Good Radiographic + Functional Outcome in a Double-Blind, Phase 3, Randomized Controlled Trial of Tocilizumab
Abstract Number: 376
Using the Multi-Biomarker Disease Activity Score As a Complementary Inclusion Criterion for Clinical Trials in Rheumatoid Arthritis May Enhance Recruitment
Abstract Number: 377
Fatigue Fluctuates Substantially over Time in Rheumatoid Arthritis Patients Despite Stable Disease Activity during Treatment with Biological Agents
Abstract Number: 378
The Use of Week 12 CDAI, RAPID3 and DAS28(CRP) Responses to Predict Optimal Response to Methotrexate
Abstract Number: 379
What Level of Disease Activity at 6 Months Predicts Achieving or Sustaining Remission at 12 Months?
Abstract Number: 380
In Palindromic Rheumatism, Older Age, Shorter Interval Between Attacks and Positive Anti-CCP Antibodies May Predict Progression to RA
Abstract Number: 381
Distribution and Clinical Significance of Anti-Heterogenic Nuclear Ribonucleoprotein A2 Antibody in Connective Tissue Diseases
Abstract Number: 382
What Is More Predictive of Achieving Remission at 12 Months: The Percentage of Baseline Improvement or the Actual Disease State Achieved at 6 Months?
Abstract Number: 383
How Low Is Low Disease Activity? an Analysis from a Prospective, Observational Registry
Abstract Number: 384
Using Patient Reported Outcome Measures to Classify Disease Activity States in Rheumatoid Arthritis: A Comparison of Patient Activity Score (PAS) and Routine Assessment of Patient Index Data (RAPID)
Abstract Number: 385
Validation of a Prognostic Model to Predict Structural Damage Assessed By X-Ray in Patients with RA Using MRI Data from a Clinical Trial
Abstract Number: 386
Association of Pharmacogenetic Markers with Treatment Response in Patients with Rheumatoid Arthritis
Abstract Number: 387
Levels of IgG Autoantibodies to Oxidation-Associated MDA Neo-Determinants Are a Biomarker for Systemic Inflammation and Disease Activity in SLE and RA
Abstract Number: 388
Soluble TREM-1 Is a Biomarker of Anti-CCP-Positive, DMARD-Naive Early Rheumatoid Arthritis
Abstract Number: 389
High 11B-HSD1 Activity Is Associated with Progression to Rheumatoid Arthritis in Patients with a New Onset of Inflammatory Arthritis
Abstract Number: 390
Prevalence and Correlates of Patient-Physician Discordance in Early Rheumatoid Arthritis
Abstract Number: 391
Self-Assessment Tool of Rheumatoid Arthritis Disease Activity: Handgrip Strength Measured By a Smartphone Connected to a Dynamometer
Abstract Number: 392
Neuroendocrine Hormone and Metabolic Peptide Levels in the Earliest Phases of Rheumatoid Arthritis – Do Free Fatty Acids Play a Role?
Abstract Number: 393
Influence of Body Mass Index on Disease Activity and Radiographic Joint Damage in Rheumatoid Arthritis : A Systematic Review and Meta-Analysis
Abstract Number: 394
Very Low or High Body Mass Index Negatively Affects patients’ Ability to Achieve Sustained Remission in Early RA in a Multicenter Canadian Cohort
Abstract Number: 395
Could Osteoprotegerin and TNF-Related Apoptosis-Inducing Ligand Assessments Help Us to Manage Early Rheumatoid Arthritis? Results from the Espoir Cohort
Abstract Number: 396
Disease Activity Scoring: Comparing Patient and Physician Global Assessment of Disease Activity in Rheumatoid Arthritis
Abstract Number: 397
Th9 Lymphocytes in Rheumatoid Arthritis
Abstract Number: 398
Anti-Rheumatic Therapy Decreases Syndecan-1 Shedding in Rheumatoid Arthritis (RA)
Abstract Number: 399
Lipid Concentrations and Particle Sizes in Drug Naive Patients with Rheumatoid Arthritis
Abstract Number: 400
Clinical Utility of 14-3-3η in the Evaluation of Inflammatory Arthritis
Abstract Number: 401
Association of Anti-Thyroid Autoantibodies with Fibromyalgia in Rheumatoid Arthritis
Abstract Number: 402
Can GP88 (Progranulin) be Used As a Biomarker for the Diagnosis and Therapy Evaluation of Rheumatoid Arthritis?
Abstract Number: 403
Metaflammation, PEDF and Chemerin: Potential Systemic Factors Which Link Obesity to Response to Therapy in Early Rheumatoid Arthritis
Abstract Number: 404
The Relationship Between Disease Activity and Levels of HMGB1 in Patients with Rheumatoid Arthritis
Abstract Number: 405
14-3-3η: A Mechanistic Biomarker That Supports the Concept of “Uncoupling” of Inflammation and Joint Damage
Abstract Number: 406
The Utility of HLA-DR Genotypification As a Complementary Tool to Discriminate Undifferentiated and Rheumatoid Arthritis Patients in Early Arthritis
Abstract Number: 407
Serum 14-3-3η Protein Supplements Traditional Rheumatoid Arthritis Biomarkers
Abstract Number: 408
14-3-3η Auto-Antibody Positivity Informs Better Clinical Outcomes in RA
Abstract Number: 409
Soluble CD163 Is a Marker of Disease Activity in Early Rheumatoid Arthritis and Reflects TNFα Levels
Abstract Number: 410
Vascular Endothelial Function Changes during Treatment in Patients with Rheumatoid Arthritis
Abstract Number: 411
ABCB1 and ABCG2 Drug-Efflux Transporters Function and Its Association with Disease Activity in a Cohort of Patients with Rheumatoid Arthritis
Abstract Number: 412
Determinants of Radiological Progression in Rheumatoid Arthritis: Relationship with Serum Levels of OPG, RANKL and DKK-1
Abstract Number: 413
Association of Antinuclear Antibodies with Lung Disease, Malignancy and Joint Replacement in Rheumatoid Arthritis
Abstract Number: 414
Relationship Between Range of Motion of Joints in Upper Limbs and Physical Function in Patients with Long-Standing Rheumatoid Arthritis: Multicenter Prospective Cohort Study for Evaluation of Joint Surgery on Physical Function
Abstract Number: 415
a Dual-Center, Double Blind Randomized Study for a New Scientific Approach in Assessment of Tender Joints in Inflammatory Arthritis Using the Smart Joint Assessor Glove Device (Smart JAG Device)
Abstract Number: 416
Using Patient Reported Outcome Measures to Classify Disease Activity States in Rheumatoid Arthritis: A Comparison of Patient-Derived Versions of Clinical Disease Activity Index (CDAI), Simplified Disease Activity Index (SDAI) and Disease Activity Score 28 (DAS28)
Abstract Number: 417
Normal Scores of “0” (floor effects) Are Seen in 33-83% of Patients with Rheumatoid Arthritis (RA) on 8 HAQ Activities Which Also Are Found on the MDHAQ, but in Fewer Than 32% of Patients on 2 Unique MDHAQ Complex Activities “Walk 2 Miles or 3 Kilometers,” and “Participate in Recreation and Sports.”
Abstract Number: 418
Prevalence of Morning Stiffness in a US Registry Population of Rheumatoid Arthritis Patients
Abstract Number: 419
Comparative Dynamics of Rheumatoid Arthritis Disease Activity and Disease Severity Measures Using Rarbis, Ciras and DAS28 in a Population Based Cohort of Patients with RA
Abstract Number: 420
Less Is More: The Shorter Physical Function Measure Promis-PF10a Outperforms HAQ in an Ethnically Diverse, Urban Rheumatoid Arthritis Clinic Population
Abstract Number: 421
Prediction of Remission By Patients and Physicians: Does the Doctor Know Best?
Abstract Number: 422
Correlation of RAPID3, DAS28 and CDAI in Disease Activity and Effects of Education Level and Co-Morbid Diseases on This Assesment in RA
Abstract Number: 423
Circulating Anti-Citrullinated Peptide Antibodies and Cytokines As Biomarkers of Response to Disease-Modifying Antirheumatic Drugs Therapy in Early Rheumatoid Arthritis
Abstract Number: 424
The Comparison Between Physical and Ultrasound Joint Examination for the Hand Joints in Patients with Rheumatoid Arthritis
Abstract Number: 425
Beyond Disease Activity: Patient Global Scores Also Reflect Treatment Expectations and Emotional Reactions to Living with Rheumatoid Arthritis
Abstract Number: 426
Exploring the DAS: What Is the Level of Agreement in the Classification of Remission and Low Disease Activity (LDA) Among the Various Versions of the Disease Activity Score (DAS) and Their Correlation? an Analysis from a Prospective, Observational Registry
Abstract Number: 427
Multimedia Patient Education Tool for Patients with Rheumatoid Arthritis
Abstract Number: 428
Patient-Physician Discordance of Disease Activity Assessments Predicts Inadequate Treatment Response in Early Rheumatoid Arthritis
Abstract Number: 429
Investigation of MRI Bone Changes in Early-Stage RA Patients Achieved in Sustained Clinical Good Response: Sub-Analysis from Nagasaki University Early Arthritis Cohort
Abstract Number: 430
Minimally Important Difference in the European Quality of Life-Five Dimensions in Patients with Rheumatoid Arthritis
Abstract Number: 431
Joint Dermal Temperature Specifically Identifies the Individual RA Patient Most Likely to Develop Radiographic Change on Sharp Score; An Exam in Less Than a Minute Can Predict Who Specifically Needs Biologic Therapy
Abstract Number: 432
Rheumatoid Arthritis-Associated Interstitial Lung Disease: Risk Factors for Disease Progression

« View all sessions from this meeting

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

© COPYRIGHT 2023 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences